Blackstone Inc
DAWN

Blackstone Inc’s Day One Biopharmaceuticals DAWN Stock Holding History

Blackstone Inc’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$891K Buy
+41,567
New +$586K ﹤0.01% 252

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Blackstone Inc's DAWN Position: Q1 2026 in Review

Blackstone Inc opened a new position in Day One Biopharmaceuticals (DAWN) in Q1 2026: 41,567 shares worth $891K. The stake represents ﹤0.01% of the portfolio and ranks #252 among its holdings.

206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Blackstone Inc held 41,567 shares of Day One Biopharmaceuticals worth $891K as of Q1 2026.
  • Day One Biopharmaceuticals was a new Blackstone Inc position in Q1 2026.
  • Day One Biopharmaceuticals made up ﹤0.01% of Blackstone Inc's portfolio in Q1 2026, its #252 holding.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Blackstone Inc's 13F filing for Q1 2026, filed 15 May 2026.